JP2019524887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524887A5 JP2019524887A5 JP2019530366A JP2019530366A JP2019524887A5 JP 2019524887 A5 JP2019524887 A5 JP 2019524887A5 JP 2019530366 A JP2019530366 A JP 2019530366A JP 2019530366 A JP2019530366 A JP 2019530366A JP 2019524887 A5 JP2019524887 A5 JP 2019524887A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antagonist
- ctla
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 23
- 238000000034 method Methods 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 239000005557 antagonist Substances 0.000 claims 20
- 108010002350 Interleukin-2 Proteins 0.000 claims 14
- 229960000074 biopharmaceutical Drugs 0.000 claims 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 10
- 108090001007 Interleukin-8 Proteins 0.000 claims 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 10
- 102100037850 Interferon gamma Human genes 0.000 claims 9
- 108010074328 Interferon-gamma Proteins 0.000 claims 9
- 108090001005 Interleukin-6 Proteins 0.000 claims 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 9
- 102000000588 Interleukin-2 Human genes 0.000 claims 7
- 102000004889 Interleukin-6 Human genes 0.000 claims 7
- 102000004890 Interleukin-8 Human genes 0.000 claims 7
- 238000003556 assay Methods 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 238000003782 apoptosis assay Methods 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000005522 programmed cell death Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 229940123751 PD-L1 antagonist Drugs 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 230000002055 immunohistochemical effect Effects 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 229950007217 tremelimumab Drugs 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000013000 chemical inhibitor Substances 0.000 claims 1
- 201000000787 conjunctival cancer Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002731 protein assay Methods 0.000 claims 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023091668A JP2023116576A (ja) | 2016-08-19 | 2023-06-02 | 癌を処置するための複数のサイトカイン成分を含有する生物製剤との、ｐｄ－１／ｐｄ－ｌ１阻害剤および／またはｃｔｌａ－４阻害剤の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377051P | 2016-08-19 | 2016-08-19 | |
| US62/377,051 | 2016-08-19 | ||
| PCT/US2017/047477 WO2018035395A1 (en) | 2016-08-19 | 2017-08-18 | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023091668A Division JP2023116576A (ja) | 2016-08-19 | 2023-06-02 | 癌を処置するための複数のサイトカイン成分を含有する生物製剤との、ｐｄ－１／ｐｄ－ｌ１阻害剤および／またはｃｔｌａ－４阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524887A JP2019524887A (ja) | 2019-09-05 |
| JP2019524887A5 true JP2019524887A5 (enExample) | 2020-10-01 |
Family
ID=61197026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530366A Pending JP2019524887A (ja) | 2016-08-19 | 2017-08-18 | 癌を処置するための複数のサイトカイン成分を含有する生物製剤との、ｐｄ−１／ｐｄ−ｌ１阻害剤および／またはｃｔｌａ−４阻害剤の使用 |
| JP2023091668A Pending JP2023116576A (ja) | 2016-08-19 | 2023-06-02 | 癌を処置するための複数のサイトカイン成分を含有する生物製剤との、ｐｄ－１／ｐｄ－ｌ１阻害剤および／またはｃｔｌａ－４阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023091668A Pending JP2023116576A (ja) | 2016-08-19 | 2023-06-02 | 癌を処置するための複数のサイトカイン成分を含有する生物製剤との、ｐｄ－１／ｐｄ－ｌ１阻害剤および／またはｃｔｌａ－４阻害剤の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200330557A1 (enExample) |
| EP (1) | EP3500290A4 (enExample) |
| JP (2) | JP2019524887A (enExample) |
| KR (1) | KR20190082192A (enExample) |
| CN (1) | CN109890405A (enExample) |
| AU (1) | AU2017312121A1 (enExample) |
| BR (1) | BR112019003248A2 (enExample) |
| CA (1) | CA3034266A1 (enExample) |
| EA (1) | EA201990530A1 (enExample) |
| MX (1) | MX2019002023A (enExample) |
| PH (1) | PH12019550027A1 (enExample) |
| SG (1) | SG11201901271VA (enExample) |
| WO (1) | WO2018035395A1 (enExample) |
| ZA (1) | ZA201901258B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| EP3675905A4 (en) * | 2017-08-30 | 2021-09-22 | Sanford Burnham Prebys Medical Discovery Institute | TP53 AS A BIOMARKER FOR RESPONSE TO IMMUNOTHERAPY |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020013883A (es) * | 2018-06-22 | 2021-05-27 | Xylonix Ip Holdings Pte Ltd | Tratamientos oncológicos con agentes de zinc. |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CN110746493A (zh) * | 2019-09-06 | 2020-02-04 | 中国药科大学 | 一种pd-l1拮抗剂多肽及其应用 |
| CN114599396A (zh) * | 2019-10-11 | 2022-06-07 | 庆北大学校产学协力团 | 包含外泌体pd-l1的表达抑制剂作为活性成分的用于增强抗癌作用的组合物 |
| HUE069670T2 (hu) * | 2019-12-27 | 2025-04-28 | Wuhan Vast Conduct Science Found Co Ltd | Készítmény és módszer a sclerosis multiplex kezelésére |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| CN113450877B (zh) * | 2021-06-28 | 2022-04-08 | 深圳裕泰抗原科技有限公司 | 一种基于多重免疫组化技术的生物标志物分析方法及其应用 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| WO2024215753A2 (en) * | 2023-04-10 | 2024-10-17 | Oregon Health & Science University | Combination therapy for treatment of solid tumors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010248761B2 (en) * | 2009-05-15 | 2016-02-11 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
| ES2816625T3 (es) * | 2010-09-24 | 2021-04-05 | Niels Grabe | Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer |
| PT3134123T (pt) * | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| KR20170066546A (ko) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
-
2017
- 2017-08-18 CA CA3034266A patent/CA3034266A1/en active Pending
- 2017-08-18 KR KR1020197007858A patent/KR20190082192A/ko not_active Ceased
- 2017-08-18 EP EP17842163.2A patent/EP3500290A4/en not_active Withdrawn
- 2017-08-18 WO PCT/US2017/047477 patent/WO2018035395A1/en not_active Ceased
- 2017-08-18 MX MX2019002023A patent/MX2019002023A/es unknown
- 2017-08-18 SG SG11201901271VA patent/SG11201901271VA/en unknown
- 2017-08-18 JP JP2019530366A patent/JP2019524887A/ja active Pending
- 2017-08-18 CN CN201780063783.XA patent/CN109890405A/zh active Pending
- 2017-08-18 AU AU2017312121A patent/AU2017312121A1/en not_active Abandoned
- 2017-08-18 EA EA201990530A patent/EA201990530A1/ru unknown
- 2017-08-18 BR BR112019003248-7A patent/BR112019003248A2/pt not_active Application Discontinuation
- 2017-08-18 US US16/326,611 patent/US20200330557A1/en not_active Abandoned
-
2019
- 2019-02-19 PH PH12019550027A patent/PH12019550027A1/en unknown
- 2019-02-27 ZA ZA201901258A patent/ZA201901258B/en unknown
-
2023
- 2023-06-02 JP JP2023091668A patent/JP2023116576A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Terry et al. | Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade | |
| Lander et al. | Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade | |
| Trujillo et al. | T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection | |
| Edwards et al. | CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti–PD-1 treatment | |
| Gatalica et al. | Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy | |
| Shosu et al. | Programmed cell death ligand 1 expression in canine cancer | |
| Aust et al. | Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer | |
| Liu et al. | The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4 | |
| Giraldo et al. | Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer | |
| JP7050702B2 (ja) | Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法 | |
| Nebiker et al. | GM-CSF production by tumor cells is associated with improved survival in colorectal cancer | |
| Remon et al. | Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer | |
| Hanna et al. | Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck | |
| Yang et al. | Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies | |
| CN107109459A (zh) | 用于分层对阻断pd1/pdl1轴的疗法的无响应者的方法 | |
| Coffey et al. | Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory B-cell malignancies | |
| JP2019524887A (ja) | 癌を処置するための複数のサイトカイン成分を含有する生物製剤との、ｐｄ−１／ｐｄ−ｌ１阻害剤および／またはｃｔｌａ−４阻害剤の使用 | |
| Li et al. | Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade | |
| JP2019505488A (ja) | 免疫介在性がん治療薬に対して応答性を示す患者の治療および選択のための方法 | |
| Moehler et al. | VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab | |
| Roberto et al. | The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets | |
| KR20230015888A (ko) | 사시투주맙 고비테칸 요법에 대한 바이오마커 | |
| Ramesh et al. | Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma | |
| WO2023081889A1 (en) | Methods for treatment of cancer | |
| Meyiah et al. | Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-naïve CRC patients |